Gambro and DaVita reach agreement on Amended Alliance and Product Supply Agreement
Gambro AB, Gambro Renal Products, Inc. and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May primarily as a result of Gambro Renal Products' inability to supply monitors due to the current Import Alert declared by the FDA.
"We are pleased to have reached this agreement with DaVita," says Jon Risfelt, President Gambro Renal Products. "DaVita is a very important customer for us and now we can focus on meeting its long-term needs and the needs of the thousands of patients DaVita serves."
The Supply Agreement was originally entered into as part of the agreement to divest Gambro's U.S. dialysis clinics to DaVita in October 2005. Under the amendment, Gambro will continue to be the preferred supplier of renal products to DaVita.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Invetech Extends its Specialized Services to the Biotechnology Market
Study identifies the off switch for biofilm formation
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention - QIAGEN's HPV testing technologies are a successful commercialization of the Nobel Prize in Medicine winner's research
List_of_drugs:_As-Az
Moonlighting protein makes a hospital germ harmful - Research team identifies potential approach for novel therapies combating Pseudomonas aeruginosa infections
New hope for treating demyelinating diseases - Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
